Drug selection for inner ear therapy
Based on their molecular properties' drugs can be identified that distribute well along the cochlea when applied intratympanically. This excludes many drugs that have been used for, or are currently in development for, inner ear therapy. On the other hand, it opens a vast array of less-studied, larger molecules, many of which would be unsuitable for oral delivery (characterized as "not druglike") but representing promising candidates for local inner ear therapy. In the earliest stages of consideration, drugs need to be selected based on the properties which govern their ability to reach the appropriate target site and not whether they are efficacious in small animals or have high potency <i>in vitro</i>. Confirmation that the selected drug is reaching the target site(s) in a large animal model should ideally precede expensive clinical trials.
Authors
- Jeremy G. Turner
- Alec N. Salt (ORCID: https://orcid.org/0000-0003-3462-9256)
Institutions
- The Turner Scientific Research Institute for Children's Orthopedics (RU)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-10-17
- DOI
- https://doi.org/10.3389/fphar.2024.1452927
- Citations
- 3
- Primary Topic
- Nicotinic Acetylcholine Receptors Study
- Type
- article
- Field-Weighted Citation Impact
- 0.70
Funders
- National Institutes of Health
- National Institute on Deafness and Other Communication Disorders